Table 2:
Setting, provider, medications, and procedures in HS encounters
| HS encounters | Number (percentage) |
|---|---|
| Setting (n=22,019)1 | |
| Outpatient | 15928 (72.3%) |
| Inpatient | 1602 (7.3%) |
| Emergency department | 1133 (5.2%) |
| Home health or skilled nursing | 547 (2.5%) |
| Prescription-only | 2809 (12.8%) |
| Provider (n=20,752)2 | |
| Dermatology | 4207 (20.3%) |
| Surgery | 4652 (22.4%) |
| Family or Internal Medicine | 10765 (51.9%) |
| Emergency medicine | 2176 (10.5%) |
| Pediatrics | 1012 (4.9%) |
| Obstetrics/Gynecology | 1361 (6.6%) |
| Prescription medications (n=22,331) | |
| Oral antibiotics | 8207 (36.8%) |
| Topical antibiotics | 2847 (12.7%) |
| Non-antibiotic systemic medications3 | 594 (2.7%) |
| pre-Humira FDA approval (n=14,009) | 334 (2.4%)4 |
| post-Humira FDA approval (n=8,322) | 260 (3.1 %)4 |
| Biologics5 | 183 (0.8%) |
| Non-biologic systemics6 | 420 (1.9%) |
| Opiates (all encounters) | 2993 (13.4%) |
| Opiates (non-procedure encounters)7 (n=20,473) | 2659 (13.0%) |
| Dermatology (n=3392) | 84 (2.5%) |
| Surgery (n=4237) | 798 (18.8%) |
| Family or Internal Medicine (n=10151) | 1259 (12.4%) |
| Emergency medicine (n=1745) | 482 (27.6%) |
| Pediatrics (n=962) | 89 (9.3%) |
| Obstetrics/Gynecology (n=1307) | 87 (6.7%) |
| Procedures (n=19,522)8 | |
| Any skin procedure | 1858 (9.5%) |
| Incision and drainage | 931 (4.8%) |
| Surgery (deroofing, biopsy, excision, reconstruction) | 248 (1.3%) |
| Injection | 675 (3.5%) |
312 encounters had more than one setting recorded (eg emergency and inpatient) and are not included
Percentages may add up to more than 100% because more than one provider could be associated with each encounter, and one provider could list more than one specialty
Non-antibiotic systemic medications included adalimumab, infliximab, anakinra, ustekinumab, cyclosporine, acitretin, isotretinoin, finasteride, and spironolactone
Chi-square comparing non-antibiotic systemics before and after FDA approval of adalimumab p=0.001
Biologic medications included adalimumab, infliximab, anakinra, and ustekinumab
Non-biologic systemic medications included cyclosporine, acitretin, isotretinoin, finasteride, and spironolactone
Percentages may add up to more than 100% because more than one provider could be associated with each encounter, and one provider could list more than one specialty. Displayed are the percentages of specialty encounters (excluding encounters with skin procedures) that had opiate prescriptions.
Any skin procedure includes all of the following: incision and drainage codes CPT 10060, 10061, 10080, 10140, 10160, 19020, 46040, 46050, and ICD-9 86.04; surgery codes CPT 10040, 11100, 11450–11471, ICD-9 86.11, 86.24; injection codes CPT 11900, 11901, HCPCS J3301